Jordan J Feld, Marcelo Cypel, Deepali Kumar, Harel Dahari, Rafaela Vanin Pinto Ribeiro, Nikki Marks, Nellie Kamkar, Ilona Bahinskaya, Fernanda Q Onofrio, Mohamed A Zahoor, Orlando Cerrochi, Kathryn Tinckam, S Joseph Kim, Jeffrey Schiff, Trevor W Reichman, Michael McDonald, Carolina Alba, Thomas K Waddell, Gonzalo Sapisochin, Markus Selzner, Shaf Keshavjee, Harry L A Janssen, Bettina E Hansen, Lianne G Singer, Atul Humar
BACKGROUND: An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). After transplantation from an infected donor, establishment of HCV infection in uninfected recipients is near-universal, with the requirement for post-transplant antiviral treatment. The aim of this study was to determine if antiviral drugs combined with an HCV entry blocker given before and for 7 days after transplant would be safe and reduce the likelihood of HCV infection in recipients of organs from HCV-infected donors...
July 2020: Lancet. Gastroenterology & Hepatology